SEC Form 4 · accession 0001178913-26-003259
Scinai Immunotherapeutics Ltd. · SCNI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amir Reichman
Officer — Chief Executive Officer · Director
Period of report
Jun 16, 2026
Accepted (ET)
Jun 18, 2026 · 2:48 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001611747
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2,F3,F4 | Jun 16, 2026 | A | 400,000,000 | $0.00 | A | 711,637,600 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Ordinary Shares are no par value per share, and are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.
- F2Includes 400,000,000 Ordinary Shares represented by restricted share units ("RSUs") granted on June 16, 2026, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates.
- F3Includes 71,637,600 Ordinary Shares represented by RSUs granted on January 25, 2024, of which 25% vested on the six-month anniversary thereof, 8.33% vested on the one-year anniversary thereof, and 66.66% vest in two equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. Each RSU represents a contingent right to receive one Ordinary Share upon vesting.
- F4Includes 240,000,000 Ordinary Shares represented by RSUs granted on December 22, 2025, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates.